Your browser doesn't support javascript.
loading
Decreased soluble Nogo-B in serum as a promising biomarker for Parkinson's disease.
Liang, Hongming; Guo, Wenyuan; He, Honghu; Zhang, Hui; Ye, Qiongyu; Zhang, Qingxin; Liao, Jiajia; Shen, Yuefei; Wang, Jin; Xiao, Yousheng; Qin, Chao.
Afiliação
  • Liang H; Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
  • Guo W; Department of Neurology, The First People's Hospital of Yulin, The Sixth Affiliated Hospital of Guangxi Medical University, Yulin, China.
  • He H; Department of Neurology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Zhang H; Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
  • Ye Q; Department of Rehabilitation Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
  • Zhang Q; Department of Rehabilitation Medicine, The First People's Hospital of Yulin, The Sixth Affiliated Hospital of Guangxi Medical University, Yulin, China.
  • Liao J; Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
  • Shen Y; Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
  • Wang J; Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
  • Xiao Y; Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
  • Qin C; Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Front Neurosci ; 16: 894454, 2022.
Article em En | MEDLINE | ID: mdl-35958994
ABSTRACT

Background:

Recently, the neurite outgrowth inhibitor-B (Nogo-B) receptor has been reported as a novel candidate gene for Parkinson's disease (PD). Nogo-B receptors need to combine with soluble Nogo-B to exert their physiological function. However, little is known about the relationship between serum soluble Nogo-B and PD.

Methods:

Serum levels of sNogo-B and α-Synuclein (α-Syn) were measured in a cohort of 53 patients with PD and 49 healthy controls with the ELISA kit method.

Results:

Serum sNogo-B level is significantly lower in the PD group than that in healthy controls and is negatively correlated with UPDRS-III score (p = 0.049), H&Y stage (p = 0.0108) as well as serum α-Syn level (p = 0.0001). The area under the curve (AUC) of serum sNogo-B in differentiating patients with PD from controls was 0.801 while the AUC of serum α-Syn was 0.93. Combining serum sNogo-B and α-Syn in differentiating patients with PD from HC presented higher discriminatory potential (AUC = 0.9534).

Conclusion:

Decreased serum sNogo-B may be a potential biomarker for PD. Lower Nogo-B level reflects worse motor function and disease progression of PD. Serum sNogo-B is of added value to serum α-Syn panel in distinguishing PD from controls. Future studies are needed to confirm in larger samples and different populations.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article